Nutritional targeting composition for improving sulforaphane release and its application
By adding Pueraria root to the nutritional targeting composition, combining sulforasulfide and melaninase, the conversion and release of sulforaphane are significantly improved, and the problem of low sulforaphane conversion in the existing composition is solved, achieving the goal of achieving More efficient absorption and utilization of sulforaphane.
Patent Information
- Application Number
- CN202311315513.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-10-11
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-10-11
AI Technical Summary
Among the existing nutritional targeting compositions, the composition containing sulforaphane and melaninase has a low conversion rate of sulforaphane in aqueous solution and a limited degree of release, which affects the utilization effect of the product.
Adding Pueraria root to the composition increases the sulforaphane conversion rate of the composition of sulforaphane and myroseinase. By combining radishoraphane with myroseinase and vitamin C, and adding pueraria root during the preparation process, it significantly improves Release of the composition in aqueous solution.
The conversion rate and release degree of sulforaphane are significantly improved, the problem of low sulforaphane release in existing compositions is overcome, and more efficient sulforaphane absorption and utilization are achieved.
Smart Images

Figure CN117100786B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine and relates to the preparation of a product for preventing or treating a disease or condition using sulforaphane and a method for increasing the release of sulforaphane in an aqueous solution. Background Art
[0002] Cancer is the leading cause of morbidity and mortality worldwide, posing a huge threat to human life and health and bringing heavy economic pressure to social development. In the long-term battle against cancer, the concept of cancer prevention was first proposed in 1976. Cancer chemoprevention refers to the use of natural or synthetic chemicals to prevent, slow down or reverse the occurrence and development of cancer and reduce the morbidity and mortality of cancer.
[0003] Precision nutrition, or nutritional targeting, is an important idea for cancer chemoprevention. Nutritional targeting is a goal proposed based on the theory of nutritional genomics. One of the main ideas of nutritional targeting is to use the active ingredients in dietary supplements such as broccoli (such as glucoraphanin and sulforaphane) to activate the Nrf2 (NF-E2-related factor 2, a transcription factor that regulates the cell's antioxidant stress response) pathway and promote the expression of phase II enzymes, thereby achieving the corresponding effect. Based on the activation effect of the Nrf2 pathway, it can not only be used for cancer chemoprevention, but also play a role in the treatment and prevention of gastric ulcers and Helicobacter pylori infection, play an antioxidant role, and has a therapeutic and preventive effect on a variety of diseases including diabetes, cardiovascular disease, Helicobacter pylori infection, autism, schizophrenia, depression, Alzheimer's disease, etc.
[0004] Sulforaphane (SFN) is chemically named 1-isothiocyanate-4-methylsulfonylbutane, also known as sulforaphane. It belongs to the class of isothiocyanates and is a bioactive substance found in broccoli that has the ability to prevent cancer. It is the strongest anti-cancer ingredient found in vegetables so far. The results of molecular mechanism studies and cell experiments on sulforaphane show that sulforaphane can activate the expression of genes related to human antioxidant capacity and metabolic detoxification by regulating the activity of phase II enzymes and the metabolites or foreign substances of phase I enzymes, thus playing a role similar to cancer chemoprevention (Myzak MC, Dashwood RH. Cancer Lett., 2006, 233: 208-18.). Sulforaphane is an extremely effective Nrf2 inducer. Its main mechanism of action is to activate the Nrf2 signaling pathway, regulate the activity of phase II enzymes (NQO1, glutathione S-transferase, γ-glutamylcysteine synthetase, glucuronyltransferase, etc.), and regulate antioxidant response elements. The prior art discloses a variety of activities and effects of sulforaphane and its precursor compound glucoraphanin, such as the prevention of colon cancer, pancreatic cancer and gastric cancer caused by Helicobacter pylori infection (CN1935003A; CN1170472C; CN101208079B). Nrf2 is a transcription factor that regulates the expression of many detoxification and antioxidant enzymes. Sulforaphane and glucoraphanin are known to have antimicrobial activity against Gram-positive and Gram-negative bacteria and yeast. On the one hand, investigations into the molecular basis of the mechanism of action of sulforaphane have shown that sulforaphane and glucoraphanin act as antioxidants indirectly by stimulating phase II detoxification enzymes, and have been shown to have a protective effect against Parkinson's disease through a mouse model, and have diuretic, antianemic and laxative abilities. On the other hand, sulforaphane and glucoraphanin, which are sulforaphane compounds, have also been shown to have anti-ultraviolet radiation properties, thereby preventing sunburn, degeneration caused by ROS (reactive oxygen species) and the occurrence of skin cancer (Talalay P.; Fahey JW; Healy ZR; Wehage SL; Benedict AL; Min C.; Dinkova-Kostova ATPNAS, 2007, 104, 17500-17505; CN104284885B), and they also protect the body from respiratory inflammation such as asthma, allergic rhinitis and chronic obstructive pulmonary disease (COPD) (RiedI MA: Saxon A.; Diaz-Sanchez D.Clinical Immunology. 2009, 130, 244-251).In recent years, it has been demonstrated that the factor Nrf2 plays an important role in growth factor regulation, signal transduction, and tissue repair (particularly, liver regeneration induced by oxidative stress) (Beyer T. et al. The EMBO Journal, 2008, 27, 212-223).
[0005] In summary, based on the above mechanisms, it has been discovered and confirmed that sulforaphane, as an isothiocyanate, has a variety of activities and functions related to its phase II enzyme regulation and Nrf2 activation. With the continuous deepening of research, through animal experiments and clinical trials, it has been found that in addition to its role in cancer chemoprevention, sulforaphane also has preventive and / or therapeutic effects on a variety of diseases including diabetes, cardiovascular disease, Helicobacter pylori infection, autism, schizophrenia, depression, Alzheimer's disease (AD), etc. For example, sulforaphane can reduce the amount of glycogen produced by the liver in patients with type 2 diabetes and lower the blood sugar content in patients (Axelsson AS et al. Sci Transl Med., 2017, 9(394)); it can reduce vascular inflammation in mice and prevent TNF-α-induced monocyte adhesion to primary epithelial cells (Nallasamy P et al. J Nutr Biochem., 2014, 25(8):824-33.); it can inhibit the colonization of Helicobacter pylori in the stomach of mice and humans and reduce gastric inflammation caused by infection (Yanaka A et al. Cancer Prev Res (Phila)., 2009, 2(4):353-60.); in clinical trials, it can reverse abnormal symptoms associated with autism, such as improving oxidative stress, low antioxidant capacity, inhibited glutathione synthesis, weakened mitochondrial capacity and oxidative phosphorylation, lipid peroxidation and neuroinflammation in patients (Singh K, et al. Proc Natl Acad Sci USA, 2014, 111(43):15550-5.); it can effectively improve the cognitive function of patients with schizophrenia (Shiina A, et al. Clin Psychopharmacol Neurosci., 2015, 13(1):62-7.); dietary intake of broccoli sprouts rich in sulforaphane has a preventive effect on depression (Zhang JC, et al. J Nutr Biochem., 2017, 39:134-144.); administration of sulforaphane can improve the cognitive function of the acute AD mouse model induced by β-amyloid protein (amyloid β-protein, Aβ) in the Y maze and passive avoidance behavior tests (Kim HV, et al. Amyloid., 2013, 20(1):7-12.).Compared to other direct antioxidants (where each molecule can only neutralize another free radical molecule and they are destroyed in the process), the antioxidant capacity of sulforaphane is more durable and effective because it activates genes involved in the protection against any oxidants or carcinogens (epigenetic factors) (Young-Joon S. Science. 2003, 3, 768). In addition, Han Li et al. reported the effect of sulforaphane on reducing pulmonary fibrosis through the Nrf2 pathway (Han Li, Jiang Tao, "Chinese Journal of New Drugs and Clinical Practice", 2016 No. 12). It is known that cruciferous plants are the main source of sulforaphane and its precursor compound glucoraphanin. Among cruciferous plants, broccoli (also known as green cauliflower, broccoli, etc., a plant of the genus Brassica in the family Cruciferae) is the main source of sulforaphane and its precursor compound glucoraphanin.
[0006] Cruciferous plants also contain other compounds, such as indoleglucosinolates, which are detrimental to the health of the body. These compounds not only have a weak ability to activate the detoxification system, but can also biologically activate the system of certain carcinogens. Therefore, broccoli is selected as a raw material and other unfavorable compounds are avoided as much as possible (CN1935003A).
[0007] It is known that the precursor glucoraphanin is present in relatively higher levels in broccoli seeds and sprouts (tender shoots). Even so, it is still unrealistic to consume an effective dose of sulforaphane by eating broccoli. Therefore, it is necessary to extract broccoli and realize its effective biological efficacy through its extract.
[0008] However, broccoli contains a biologically inactive precursor of sulforaphane, namely glucoraphanin, which requires myrosinase contained in cruciferous plants to decompose glucoraphanin and convert it into active sulforaphane. Under certain conditions, myrosinase can decompose glucosinolates to generate products including biologically active isothiocyanates. However, we found that even if myrosinase is used to convert the precursor of sulforaphane in broccoli into sulforaphane in advance, the sulforaphane in the product has poor oxygen and heat stability and is easily degraded, so it is difficult to store and use. In previous studies, the inventors found that if myrosinase and glucoraphanin raw materials are separately prepared in solid form and provided in the form of a premix, the enzyme can avoid the decomposition of glucoraphanin during storage, and the decomposition of glucoraphanin can be achieved in a solution environment after adding water or taking orally, and the effective absorption of sulforaphane can be achieved (see CN110946996A).
[0009] In our research, we found that for existing nutritional targeted compositions for cancer prevention, especially for mixtures of myrosinase and glucoraphanin raw materials (including raw materials in the form of broccoli and / or its extracts) in solid form, the conversion rate of glucoraphanin in aqueous solution is low and the release degree is limited, which affects the utilization of the product.
[0010] Therefore, it is necessary to overcome the problem of low conversion rate of sulforaphane in existing nutritional targeting compositions, especially the problem that the composition comprising glucoraphanin and myrosinase has limited release of sulforaphane in aqueous solution, and it is urgently needed to provide a composition comprising glucoraphanin and myrosinase that can improve the release of sulforaphane in aqueous solution. Summary of the invention
[0011] The present inventors unexpectedly discovered during the study that Pueraria root can significantly improve the conversion of glucoraphanin to sulforaphane. If Pueraria root is added to a composition comprising glucoraphanin, myrosinase and vitamin C, the release of the composition in aqueous solution can be greatly improved, the conversion rate of sulforaphane can be significantly increased, and the release of sulforaphane can be improved.
[0012] Based on this discovery, in a first aspect of the present invention, a nutritional targeting composition for improving the release of sulforaphane is provided, comprising the following components:
[0013] (1) providing component 1 of glucoraphanin;
[0014] (2) providing component 2 of myrosinase;
[0015] (3) Vitamin C; and
[0016] (4) Pueraria root.
[0017] In the present invention, the component 1 providing glucoraphanin can be any substance or raw material that can provide a source of glucoraphanin compounds. Preferably, the component 1 providing glucoraphanin is selected from cruciferous plants, extracts thereof and mixtures thereof. The cruciferous plants are preferably selected from broccoli, cauliflower, red cabbage, Brussels sprouts or cabbage, and broccoli is particularly preferred. The cruciferous plants can be all or part of the plant, such as the whole plant, its aerial parts, flower heads, sprouts, seeds or a combination thereof. The component 1 providing glucoraphanin can also be an extract of the cruciferous plant, such as a solvent extract, preferably a water extract, an alcohol extract, a hydroalcoholic extract. In addition to plant tissues, extracts and mixtures thereof of cruciferous plants, the component 1 providing glucoraphanin of the present invention can also include chemically synthesized, semi-chemically synthesized, enzymatically synthesized or biosynthesized glucoraphanin.
[0018] In the present invention, the component 2 providing myrosinase can be any suitable substance or raw material that can provide a source of myrosinase. Preferably, the component 2 providing myrosinase is selected from cruciferous plants, extracts thereof and mixtures thereof. Preferably, the component 2 providing myrosinase is selected from horseradish, radish and cabbage. In some preferred embodiments, the component 2 providing myrosinase is selected from extracts of horseradish, radish and cabbage; in other preferred embodiments, the component 2 providing myrosinase is selected from the juice or slurry of horseradish, radish and cabbage, or the powder obtained by drying the juice or slurry.
[0019] In the present invention, the broccoli refers to the whole or part of the broccoli plant. Preferably, the broccoli is selected from edible parts in the usual sense; more preferably, the broccoli is selected from broccoli heads, broccoli seeds and broccoli sprouts, and combinations thereof.
[0020] In the present invention, the broccoli extract refers to an extract of the whole or a part of the broccoli plant, including but not limited to extracts of the broccoli, broccoli florets, broccoli seeds and / or broccoli sprouts. On the other hand, the extract is an extract obtained by extraction using a solvent, and the extract is preferably a water extract, an alcohol extract or a hydroalcoholic extract, and particularly preferably a water extract.
[0021] In the present invention, the component 1 providing glucoraphanin is preferably selected from broccoli florets, broccoli seeds, broccoli sprouts, broccoli extracts and mixtures thereof, and chemically synthesized or biosynthesized glucoraphanin.
[0022] The kudzu root in the present invention refers to the dried root of the leguminous plant kudzu. In the composition of the present invention, the kudzu root can be in the form of a kudzu root dry powder or a kudzu root extract. Preferably, the kudzu root in the present invention is in the form of a kudzu root extract, such as a water extract, an alcohol extract or a water-alcohol extract. The alcohol can be selected from ethanol, methanol, propanol, butanol. The kudzu root extract in the present invention is preferably a dry extract.
[0023] In the present invention, the mass ratio of component 1, component 2, vitamin C and kudzu root is (10-60): (1-60): (0.1-5): (0.1-5); preferably (10-40): (1-40): (0.1-2): (0.1-1), and more preferably (10-30): (1-10): (0.1-2): (0.1-0.5). In a specific embodiment, the mass ratio of component 1: horseradish powder (component 2): vitamin C: kudzu root powder calculated based on glucoraphanin is (1-20): (2-8): (0.1-5): (0.1-10); in another specific embodiment, the mass ratio of component 1: horseradish powder (component 2): kudzu root powder calculated based on glucoraphanin is (1-10): (2-8): (0.1-2): (0.1-5); in another specific embodiment, the mass ratio of component 1: horseradish powder (component 2): vitamin C: kudzu root dry extract calculated based on glucoraphanin is (1-10): (2-8): (0.1-2): (0.1-3); in another specific embodiment, the mass ratio of component 1: horseradish powder (component 2): vitamin C: kudzu root dry water extract calculated based on glucoraphanin is (1-10): (2-8): (0.1-2): (0.1-3).
[0024] In some embodiments, the nutritionally targeted composition of the present invention for improving sulforaphane release may consist of the following components:
[0025] (1) providing component 1 of glucoraphanin;
[0026] (2) providing component 2 of myrosinase;
[0027] (3) Vitamin C; and
[0028] (4) Pueraria root.
[0029] The composition of the present invention is preferably in solid form, for example, it can be in the form of a powder, granule, capsule or tablet. More preferably, in the composition of the present invention, the component 1, component 2 and kudzu root are all in solid form. For example, the component 1 can be in the form of a powder (including freeze-dried powder) of an extract, sprout or seed; the component 2 can be in the form of a dry powder, a dry extract (including freeze-dried powder); the kudzu root can be in the form of a kudzu root dry powder or a dry extract (preferably a dry water extract).
[0030] In some preferred embodiments, component 1 of the present invention is selected from broccoli seed extract, broccoli sprout powder, broccoli floret freeze-dried powder and mixtures thereof.
[0031] In another aspect, the present invention provides a use of the nutritional targeted composition for improving sulforaphane release of the present invention in the preparation of a product for preventing and / or treating a disease or condition that can be prevented and / or treated by sulforaphane. The product may be a medicine or a food. Preferably, the product is a medicine. In some preferred embodiments, the disease or condition that can be prevented and / or treated by sulforaphane is selected from cancer, diabetes, cardiovascular disease, Helicobacter pylori infection, autism, schizophrenia, depression, Alzheimer's disease (AD) and pulmonary fibrosis.
[0032] In another aspect, the present invention provides a method for converting glucoraphanin into sulforaphane in vitro, comprising the following steps:
[0033] 1) providing a nutritional targeting composition for improving sulforaphane release according to the present invention,
[0034] 2) Mixing the composition with water or an aqueous solution.
[0035] In another aspect, the present invention also provides a method for supplementing sulforaphane to a subject in need thereof, comprising administering to the subject a nutritionally targeted composition for improving sulforaphane release as described in the present invention.
[0036] In another aspect, the present invention also provides a method for promoting the release of sulforaphane in an aqueous solution, comprising the step of mixing component 1 providing glucoraphanin, component 2 providing myrosinase, vitamin C and kudzu root.
[0037] In yet another aspect, the present invention also provides a use of a combination of Pueraria root and vitamin C in preparing a product for promoting the release of sulforaphane in an aqueous solution.
[0038] The present inventors unexpectedly discovered that by adding Pueraria root to the composition, the conversion rate of sulforaphane released from the composition comprising glucoraphanin, myrosinase and vitamin C in water can be effectively improved, thereby obtaining an increased release of sulforaphane and effectively overcoming the problem of low sulforaphane release. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 is a bar graph showing the release of sulforaphane from the composition of the present invention (powder) and the control composition in aqueous solution;
[0040] Figure 2 It is a bar graph showing the release of sulforaphane from the composition of the present invention (tablet) and the control composition in aqueous solution. DETAILED DESCRIPTION
[0041] Preparation Example 1: Preparation of Compositions 1-2 (Powders) of the Invention and Control Compositions
[0042] Preparation of the composition 1 of the present invention: 600 g of broccoli seed water extract (containing 13.0% glucoraphanin, from Brassica Protection Products LLC, USA, hereinafter the same), 60 g of horseradish powder, 6 g of vitamin C, and 15 g of kudzu root powder were mixed evenly to obtain 0.681 kg of the composition 1, in which glucoraphanin accounted for 11.45%. The above composition was divided into small bags with a weight of 5 g per bag to obtain the corresponding powder product (the composition 1 of the present invention).
[0043] Preparation of the composition 2 of the present invention: 600 g of broccoli seed water extract (containing 13.0% glucoraphanin), 60 g of horseradish powder, 6 g of vitamin C and 120 g of kudzu root powder were mixed evenly to obtain 0.786 kg of the composition 2, in which glucoraphanin accounted for 9.92%. The composition 2 was divided into small bags with a weight of 5 g per bag to obtain the corresponding powder product (the composition 2 of the present invention).
[0044] Preparation of Composition 3 of the present invention: 400 g of broccoli seed water extract (containing 13.0% glucoraphanin, from Brassica Protection Products LLC, USA, hereinafter the same), 60 g of horseradish powder, 6 g of vitamin C and 15 g of kudzu root extract (dried water extract) were mixed uniformly to obtain 0.481 kg of Composition 3, in which glucoraphanin accounted for 10.81%. The above composition was divided into small bags with a weight of 5 g per bag to obtain the corresponding powder product (Composition 3 of the present invention).
[0045] Preparation of the control composition: 600 g of broccoli seed water extract (containing 13.0% glucoraphanin), 60 g of horseradish powder, 6 g of vitamin C and 15 g of starch were mixed evenly to obtain 0.681 kg of the control composition, in which glucoraphanin accounted for 11.45%. The control composition was divided into small bags with a weight of 5 g per bag to obtain the corresponding powder product (control composition).
[0046] Example 2 :Determination of in vitro release curve of powder:
[0047] 1 g of each of the above four powder products was taken and dissolved in 30 ml of artificial gastric juice at 37°C (prepared according to the 2015 edition of the Chinese Pharmacopoeia and adjusted to pH 3.5 to simulate postprandial gastric juice conditions) for reaction. At the 30th minute, a sample was taken to determine the content of sulforaphane in the aqueous solution by HPLC, and the formation rate of sulforaphane was calculated.
[0048] HPLC determination method of sulforaphane: Take the sample solution, pass it through a 0.45μm filter membrane, and perform HPLC analysis. HPLC conditions: chromatographic column: Huapu Unitary C18 (4.6mm×250mm, 5μm); column temperature: 30℃; mobile phase: 70% water-30% acetonitrile; flow rate: 0.8mL / min; injection volume: 10μL; UV detection wavelength: 245nm.
[0049] The experimental results are shown in Table 1 below.
[0050] Table 1. Comparison of sulforaphane release from the powder products of the present invention compositions 1-3 and the control composition
[0051] Powder Group 30min Sulforaphane production rate (%) Composition 1 of the present invention 74.1% Composition 2 of the present invention 78.4% Composition 3 of the present invention 75.9% Control composition 24.8%
[0052] From the experimental results, it can be seen that compared with the control composition without Pueraria root, the compositions 1-3 of the present invention containing Pueraria root have improved sulforaphane release characteristics in aqueous solution, and the sulforaphane conversion rate is significantly improved, all of which are increased by more than 2 times. Such a result is unexpected.
[0053] Preparation Example 2 : Preparation of the composition (tablet) of the present invention and its control tablet
[0054] (1) Preparation of the composition of the present invention (tablet 1): 600 g of broccoli sprout water extract (containing 13.0% glucoraphanin), 150 g of horseradish powder, 12 g of vitamin C, 15 g of kudzu root powder and 750 g of other tableting excipients (specifically composed of starch, maltodextrin, and hydroxypropylmethylcellulose in a ratio (w / w) of 5:80:2, the same below) were mixed evenly, tableted at a tablet weight of 1 g / tablet, and film-coated to obtain about 1.527 kg of the tablet of the present invention, in which glucoraphanin accounts for 5.11%. The tablets of the present invention were packed into bottles at a rate of 60 tablets per bottle, and the bottle mouth was sealed after adding a desiccant to obtain the corresponding tablet product.
[0055] (2) Preparation of the composition of the present invention (tablet 2): 600 g of broccoli sprout water extract (containing 13.0% glucoraphanin), 150 g of horseradish powder, 12 g of vitamin C, 15 g of kudzu root extract (dried water extract) and 750 g of other tableting excipients were mixed evenly, tableted at a tablet weight of 1 g / tablet, and film-coated to obtain about 1.527 kg of tablets 2, in which glucoraphanin accounted for 5.11%. The tablets 2 were packed into bottles at a rate of 60 tablets per bottle, and the bottles were sealed after adding a desiccant to obtain the corresponding tablet products.
[0056] (3) Preparation of control tablets: 600 g of broccoli sprout water extract (containing 13.0% glucoraphanin), 150 g of horseradish powder, 12 g of vitamin C, 15 g of starch and 750 g of other tableting excipients were mixed evenly, tableted at a tablet weight of 1 g / tablet, and film-coated to obtain about 1.527 kg of control tablets, of which glucoraphanin accounted for 5.11%. The control tablets were packed into bottles at a rate of 60 tablets per bottle, and the bottles were sealed after adding desiccant to obtain the corresponding tablet products.
[0057] Example 3 :Determination of in vitro release curve of tablets:
[0058] 2 g of each of the four tablet products prepared in Preparation Example 2 was dissolved in 30 ml of artificial gastric juice at 37° C. (prepared according to the 2015 edition of the Chinese Pharmacopoeia and adjusted to pH 3.5 to simulate postprandial gastric juice conditions) for reaction. Samples were taken at 30 minutes to determine the content of sulforaphane in the aqueous solution by HPLC, and the formation rate of sulforaphane was calculated.
[0059] HPLC determination method of sulforaphane: Take the above sample solution, pass it through a 0.45μm filter membrane, and perform HPLC analysis. HPLC conditions: chromatographic column: Huapu Unitary C18 (4.6mm×250mm, 5μm); column temperature: 30℃; mobile phase: 70% water-30% acetonitrile; flow rate: 0.8mL / min; injection volume: 10μL; UV detection wavelength: 245nm.
[0060] The experimental results are shown in Table 2 below.
[0061] Table 2. Comparison of sulforaphane release from tablets 1-2 of the composition of the present invention and the control tablet
[0062] Tablet Group 30min Sulforaphane production rate (%) Tablet 1 of the present invention 71.2% Tablet 2 of the present invention 71.9% Control tablets 23.9%
[0063] From the experimental results, it can be seen that compared with the control tablets without Pueraria root, the tablets of the present invention containing Pueraria root have significantly improved sulforaphane release characteristics in aqueous solution, and the sulforaphane conversion rate is significantly improved, both of which are increased by more than 2 times. Such results are unexpected.
[0064] It should be understood that, although the present invention is specifically disclosed by preferred embodiments, those skilled in the art may adopt the optional features, modifications, improvements and variations of the present invention embodied by the content disclosed herein, and it is considered that these modifications, improvements and variations are within the scope of the present invention. The materials, methods and embodiments provided herein as exemplary preferred example schemes are exemplary and are not intended to limit the scope of the present invention.
Claims
1. A nutritional targeted composition for improving the release of sulforaphane, comprising the following components composition: 1) Providing component 1 of glucoraphanin; 2) providing component 2 of myrosinase; 3) Vitamin C; and 4) Pueraria root, Component 1 is broccoli seed water extract or broccoli sprout water extract, component 2 is horseradish powder, and kudzu root is kudzu root powder or kudzu root water extract; the mass ratio of component 1, component 2, vitamin C and kudzu root is (10-60): (1-60): (0.1-2): (0.1-5).
2. The composition according to claim 1, which is in the form of a powder or tablet.
3. A method for promoting the release of sulforaphane in an aqueous solution, comprising the step of mixing component 1 providing glucoraphanin, component 2 providing myrosinase, vitamin C and kudzu root, wherein component 1 is a broccoli seed water extract or a broccoli sprout water extract, component 2 is horseradish powder, and kudzu root is kudzu root powder or kudzu root water extract; and the mass ratio of component 1, component 2, vitamin C and kudzu root is (10-60): (1-60): (0.1-2): (0.1-5).
